Diagnosis and treatment of severe pediatric pulmonary hypertension

Cardiology in Review

Volumn 9, Issue 4, 2001, Pages 227-237

  Ivy, D ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Congenital heart disease; Endothelin; Nitric oxide; Pulmonary hypertension

Indexed keywords

VASODILATOR AGENT; WARFARIN;

ANTICOAGULANT THERAPY; HUMAN; LUNG ARTERY PRESSURE; PULMONARY HYPERTENSION; REVIEW; TREATMENT INDICATION;

EID: 0034933319     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045415-200107000-00009     Document Type: Review

References (65)

1. Recent advances in the treatment of pediatric pulmonary artery hypertension
2. Primary pulmonary hypertension in children: Clinical characterization and survival
3. Echocardiographic evaluation of pulmonary hypertension
4. Regulation of the pulmonary circulation
5. Second natural history study of congenital heart defects: Results of treatment of patients with ventricular septal defects
6. Surgical treatment of adult atrial septal defect: Early and long-term results
7. Pulmonary vascular disease in complete transposition of the great arteries: A study of 200 patients
8. Primary pulmonary hypertension
9. Genetic anticipation and abnormal gender ratio at birth in familial primary pulmonary hypertension
10. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium
11. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene
12. Vasodilator therapy for primary pulmonary hypertension in children
13. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension
14. Primary pulmonary hypertension: Natural history and the importance of thrombosis
15. Nitric oxide and endothelin-1 in pulmonary hypertension
16. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension
17. The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt
18. Eisenmenger syndrome in adults: Ventricular septal defect, truncus arteriosus, univentricular heart
19. Risk of stroke in adults with cyanotic congenital heart disease
20. The Eisenmenger syndrome in adults
21. Evaluation of patients with suspected chronic thromboembolic pulmonary hypertension
22. Long-term outcome after pulmonary thromboendarterectomy
23. Cor pulmonale
24. The Registry of the International Society of Heart and Lung Transplantation: Third Official Pediatric Report - 1999
25. Pathophysiology and treatment of bronchopulmonary dysplasia: Current issues
26. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension
27. Pulmonary hypertension: Pathophysiology as a basis for clinical decision making
28. Recent advances in the study of pulmonary hypertension
29. Magnification pulmonary wedge angiography in the evaluation of children with congenital heart disease and pulmonary hypertension
30. Plexogenic arteriopathy
31. Inhaled nitric oxide to test the vasodilator capacity of the pulmonary vascular bed in children with long-standing pulmonary hypertension and congenital heart disease
32. Assessment and follow-up of patients with ventricular septal defect and elevated pulmonary vascular resistance
33. Inhaled nitric oxide in congenital heart disease
34. Combined effects of nitric oxide and oxygen during acute pulmonary vasodilator testing
35. Vascular structure in lung tissue obtained at biopsy correlated with pulmonary hemodynamic findings after repair of congenital heart defects
36. Atrial natriuretic peptide and nitric oxide in children with pulmonary hypertension after surgical repair of congenital heart disease
37. Pulmonary vasodilatory effects of 12 and 60 parts per million inhaled nitric oxide in children with ventricular septal defect
38. Thromboxane A2 and prostacyclin biosynthesis in children and adolescents with pulmonary vascular disease
39. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonaryhypertension
40. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension
41. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects
42. Chronic effects of oral prostacyclin analogue on thromboxane A2 and prostacyclin metabolites in pulmonary hypertension
43. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue
44. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension
45. Use of inhaled nitric oxide and acetylcholine in the evaluation of pulmonary hypertension and endothelial function after cardiopulmonary bypass
46. Inhaled nitric oxide in the neonate with cardiac disease
47. Nitric oxide and prostacyclin treatment of an infant with primary pulmonary hypertension
48. Acute hemodynamic effects of pulsed delivery of low flow nasal nitric oxide in children with pulmonary hypertension
49. Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension: An ambulatory delivery system and initial clinical tests
50. Minimizing the inhaled dose of NO with breath-by-breath delivery of spikes of concentrated gas
51. Dipyridamole attenuates rebound pulmonary hypertension after inhaled nitric oxide withdrawal in postoperative congenital heart disease
52. Effects of dipyridamole and inhaled nitric oxide in pediatric patients with pulmonary hypertension
53. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal
54. Endothelins and endothelin receptor antagonists: Therapeutic considerations for a novel class of cardiovascular drugs
55. Endothelin-1 and endothelin-receptors in lung biopsies of patients with pulmonary hypertension due to congenital heart disease
56. Prolonged endothelin A receptor blockade attenuates chronic pulmonary hypertension in the ovine fetus
57. Early therapeutic experience with the endothelin antagonist BQ-123 in pulmonary hypertension after congenital heart surgery
58. Hemodynamic effects of Bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension
59. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor
60. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension
61. Lung transplantation in children and young adults with cardiovascular disease
62. Outcome of infants listed for lung or heart/lung transplantation
63. Effects of atrial septostomy in patients with terminal cor pulmonale due to pulmonary vascular disease
64. Blade balloon atrial septostomy in patients with severe primary pulmonary hypertension